Roivant Sciences Ltd.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-21 EDT			5-day change	1st Jan Change
36.80 ^USD	+5.38%		+9.46%	+69.59%

10-21	Roivant Sciences Ltd. - Special Call
10-21	AI Leaders Rally, Service Giants Retrench

Published on 09/08/2026 at 09:37 am EDT - Modified on 09/08/2026 at 12:36 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Mosliciguat in PH-ILD PHocus Study Top Line Results Conference Call. [Operator Instructions]

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-21	Roivant Sciences Ltd. - Special Call
10-21	AI Leaders Rally, Service Giants Retrench
10-21	Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis	MT
09-23	US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks	MT
09-23	Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus	MT
09-22	Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12:20 PM
09-17	Stifel Nicolaus Initiates Roivant Sciences With Buy Rating, $51 Price Target	MT
09-10	Roivant Sciences Ltd. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10:00 AM
09-09	Roivant Sciences Ltd. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 01:00 PM
09-08	Top Midday Gainers	MT
09-08	Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM
09-08	Roivant Sciences Ltd. - Special Call
09-08	US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs	MT
09-08	Top Premarket Gainers	MT
09-08	Roivant Announces Positive Results From Phase 2 PHocus Clinical Trial And Unveils Ongoing Phase 3 PHrontier Study	CI